David covers investment, R&D and alliance deal trends as well as regulatory statistics that impact policy initiatives in Washington. Prior to joining BIO, David spent over a decade in the biotech industry as a biochemist in drug discovery at Amgen, Millennium and Novartis, and later in synthetic biology at the J Craig Venter Institute. David is also a financial analyst specializing in risk-adjusted DCF models and holds the Chartered Financial analyst (CFA) designation.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
1201 Maryland Avenue SW, Suite 900, Washington, DC, 20024 ・ 202-962-9200
© BIO 2020 All Rights Reserved